Bausch Health Companies (BHC) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bausch Health Companies (BHC) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 36.3% versus a loss of 6.1%. Bausch Health Companies is the larger company by market cap ($3.08 billion vs $2.84 billion), about 1.1 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +6.7%). Bausch Health Companies converts more of its revenue into profit, with a net margin of 1.5% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | TLX |
|---|---|---|
| Share price | $8.22 | $8.37 |
| Market cap | $3.08B | $2.84B |
| 1-day change | -3.97% | -3.90% |
| YTD return | +18.27% | +11.75% |
| 1-year return | +36.32% | -6.06% |
| 5-year return | -67.45% | — |
| P/E ratio (TTM) | — | 83.70 |
| Forward P/E | 1.89 | — |
| EPS (TTM) | $-2.26 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $803.79M |
| Revenue growth (YoY) | +6.66% | +55.61% |
| Net income (latest FY) | $157.00M | $-7.13M |
| Gross margin | — | 53.05% |
| Operating margin | 17.66% | 3.70% |
| Net margin | 1.53% | -0.89% |
| 52-week high | $9.04 | $13.11 |
| 52-week low | $4.33 | $6.28 |
| Distance from 52-week high | -9.07% | -36.16% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +2.19% | +134.89% |
| Average volume | 3.16M | 356.74K |
| Shares outstanding | 374.27M | 339.78M |
| Employees | 20,300 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHC has outperformed TLX by 42.4 percentage points over the past year.
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +6.66%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
BHC vs TLX FAQ
Which is bigger, Bausch Health Companies or Telix Pharmaceuticals?
Bausch Health Companies (BHC) is larger, with a market capitalization of $3.08B compared with $2.84B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, BHC or TLX?
BHC returned +36.32% over the past 12 months, compared with -6.06% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.